Healthcare

The first drugs using the CRISPR technique are approaching the market, with the potential to transform the lives of people with certain genetic illnesses. We talked with Dr. Greg Licholai about the state of the technology.

A new study co-authored by Yale SOM’s Mushfiq Mobarak investigated how mental health fared after the pandemic arrived in eight low- and middle-income countries, and found signs of a sharp, and lasting, deterioration.

In a new paper, Yale SOM’s Soheil Ghili and his co-authors show that longer health insurance contracts could protect consumers who are or become ill against sudden premium spikes.

In the wake of the Supreme Court’s Dobbs v. Jackson Women’s Health Organization decision, access to reproductive healthcare varies widely from state to state. In a recent Yale SOM conversation, alumni and faculty discussed how businesses can advocate for the preservation of that access on behalf of their employees, customers, and other stakeholders.

We asked Prof. Fiona Scott Morton, an expert on competition in the healthcare industry, whether the new legislation will make a difference—and what it will take to get drug prices under control.

Amanda Skinner ’08, CEO and president of Planned Parenthood of Southern New England, discusses the consequences of the Dobbs v. Jackson Women’s Health Organization decision for women’s health and economic lives, and for her organization.

Eric Tichy ’18, vice chair of pharmacy formulary at the Mayo Clinic, explains what’s driving pharmaceutical spending and what the trends mean for patients, providers, and pharma companies.

The homes’ strong internal identity means that wrongdoing is less likely to be flagged for an outside regulator’s involvement, allowing problems to worsen, suggests new research co-authored by Yale SOM’s Amandine Ody-Brasier.

New research based on data on COVID-19 RNA in sewage suggests that many more people had been infected with COVID-19 by May 2021 than official case counts indicated.